Sirolimus and cyclosporin for renal transplantation.
Halloran
P F
PF
Division of Nephrology and Immunology, University of Alberta, Edmonton, Canada.
D065095:Calcineurin Inhibitors; D002352:Carrier Proteins / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D016572:Cyclosporine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004357:Drug Synergism; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D020104:Immunophilins / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D016030:Kidney Transplantation; D019696:Peptidylprolyl Isomerase / Q000378:metabolism; D017853:Phosphotransferases (Alcohol Group Acceptor); D011485:Protein Binding; D014176:Protein Biosynthesis / Q000187:drug effects; D012333:RNA, Messenger / Q000187:drug effects; D020123:Sirolimus / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D016559:Tacrolimus / Q000378:metabolism / Q000627:therapeutic use; D022021:Tacrolimus Binding Proteins
D065095:Calcineurin Inhibitors; D002352:Carrier Proteins; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D016572:Cyclosporine; D017853:Phosphotransferases (Alcohol Group Acceptor); C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D022021:Tacrolimus Binding Proteins; D020104:Immunophilins; D019696:Peptidylprolyl Isomerase; D020123:Sirolimus; D016559:Tacrolimus